Rilpivirine Injectable Suspension — Competitive Intelligence Brief

Rilpivirine Injectable Suspension (Rilpivirine Injectable Suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease / Virology.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Rilpivirine Injectable Suspension (Rilpivirine Injectable Suspension) — ViiV Healthcare. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rilpivirine Injectable Suspension TARGET	Rilpivirine Injectable Suspension	ViiV Healthcare	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
rilpivirina + emtricitabina + tenofovir	rilpivirina + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
TAF/FTC FDC	TAF/FTC FDC	Janssen Scientific Affairs, LLC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class